1. Home
  2. LSTA vs PIII Comparison

LSTA vs PIII Comparison

Compare LSTA & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSTA
  • PIII
  • Stock Information
  • Founded
  • LSTA 1980
  • PIII 2015
  • Country
  • LSTA United States
  • PIII United States
  • Employees
  • LSTA N/A
  • PIII N/A
  • Industry
  • LSTA Misc Health and Biotechnology Services
  • PIII Medical/Nursing Services
  • Sector
  • LSTA Health Care
  • PIII Health Care
  • Exchange
  • LSTA Nasdaq
  • PIII Nasdaq
  • Market Cap
  • LSTA 31.2M
  • PIII 32.2M
  • IPO Year
  • LSTA N/A
  • PIII N/A
  • Fundamental
  • Price
  • LSTA $2.61
  • PIII $0.20
  • Analyst Decision
  • LSTA Strong Buy
  • PIII Buy
  • Analyst Count
  • LSTA 1
  • PIII 3
  • Target Price
  • LSTA $15.00
  • PIII $2.38
  • AVG Volume (30 Days)
  • LSTA 70.3K
  • PIII 5.6M
  • Earning Date
  • LSTA 02-27-2025
  • PIII 03-27-2025
  • Dividend Yield
  • LSTA N/A
  • PIII N/A
  • EPS Growth
  • LSTA N/A
  • PIII N/A
  • EPS
  • LSTA N/A
  • PIII N/A
  • Revenue
  • LSTA N/A
  • PIII $1,476,630,000.00
  • Revenue This Year
  • LSTA N/A
  • PIII $21.45
  • Revenue Next Year
  • LSTA N/A
  • PIII N/A
  • P/E Ratio
  • LSTA N/A
  • PIII N/A
  • Revenue Growth
  • LSTA N/A
  • PIII 25.38
  • 52 Week Low
  • LSTA $2.19
  • PIII $0.17
  • 52 Week High
  • LSTA $4.20
  • PIII $1.22
  • Technical
  • Relative Strength Index (RSI)
  • LSTA 42.17
  • PIII 49.82
  • Support Level
  • LSTA $2.45
  • PIII $0.17
  • Resistance Level
  • LSTA $2.74
  • PIII $0.20
  • Average True Range (ATR)
  • LSTA 0.32
  • PIII 0.02
  • MACD
  • LSTA -0.05
  • PIII 0.00
  • Stochastic Oscillator
  • LSTA 16.48
  • PIII 65.71

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Share on Social Networks: